3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Anorexia
5
Neoplasms
4
Weight Loss
2
Pancreatic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Cachexia
2
Breast Neoplasms
2
Sleep Initiation and Maintenance Disorders
1
Neoplasm Metastasis
1
Malnutrition
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Depressive Disorder, Major
1
Depression
1
Body Weight
1
Anorexia Nervosa with Significantly Low Body Weight
1
Advanced Cancer
1
Interventions
Surveys and Questionnaires
7
Standard of Care
5
Sirolimus
5
Bevacizumab
5
temsirolimus
4
Interviews as Topic
4
Paclitaxel
3
olaparib
2
Vorinostat
2
Olanzapine
2
Magnetic Resonance Spectroscopy
2
Gemcitabine
2
Everolimus
2
Erlotinib Hydrochloride
2
Dasatinib
2
Cetuximab
2
zaleplon
1
vistusertib
1
tilsotolimod
1
pazopanib
1
olanzapine-fluoxetine combination
1
nimotuzumab
1
liposomal doxorubicin
1
capivasertib
1
apatinib
1
Videotape Recording
1
Vemurafenib
1
Valproic Acid
1
Trastuzumab
1
Topotecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Advanced Cancer
×
Mirtazapine
×
Clear all
NCT03254173
2020-02-05
MCACS100
Kasr El Aini Hospital
Phase 2/3
Completed
120 enrolled